AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Pipeline Review on Hepatitis C Virus Envelope Protein E2 - H2 2020 - ResearchAndMarkets.com

December 31, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 31, 2020--

The “Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020” drug pipelines have been added to ResearchAndMarkets.com’s offering.

According to the recently published report ‘Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020’; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 9 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

ADVERTISEMENT

Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.

The report ‘Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020’ outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
  • The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

ADVERTISEMENT

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

1.Introduction

2. Hepatitis C Virus Envelope Protein E2 - Overview

3. Hepatitis C Virus Envelope Protein E2 - Therapeutics Development

  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

4. Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment

  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

5. Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development

  • Ennaid Therapeutics LLC
  • Integrated BioTherapeutics Inc
  • Toray Industries Inc

6. Hepatitis C Virus Envelope Protein E2 - Drug Profiles

7. Hepatitis C Virus Envelope Protein E2 - Discontinued Products

8. Hepatitis C Virus Envelope Protein E2 - Product Development Milestones

  • Featured News & Press Releases
  • Jun 10, 2013: IBT and Stanford Awarded STTR

9. Appendix

  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

Companies Mentioned

  • Ennaid Therapeutics LLC
  • Integrated BioTherapeutics Inc
  • Toray Industries Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ytfnhu

View source version on businesswire.com:https://www.businesswire.com/news/home/20201231005066/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL GENETICS HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/31/2020 05:41 AM/DISC: 12/31/2020 05:41 AM

http://www.businesswire.com/news/home/20201231005066/en